Scancell HoldingsSCNLF 20 EBIT per Share is $-0.01 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,180 Biotechnology companies, Scancell Holdings ranks worse than 67.88% on this metric.
Scancell Holdings's EBIT per Share for the
six
months ended in Oct. 2025 was $-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2025 was $-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 2.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -2.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -1.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Scancell Holdings's EBIT per Share or its related term are showing as below:
SCNLF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -21.6 Med: -2.45 Max: 51.3
Current: 2.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Scancell Holdings was 51.30% per year. The lowest was -21.60% per year. And the median was -2.45% per year.
SCNLF's 3-Year EBIT Growth Rate is ranked worse than 67.88% of 1180
companies
in the Biotechnology industry
Industry Median: 15.55
vs SCNLF: 2.10
Scancell Holdings (OTCPK:SCNLF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Scancell Holdings EBIT per Share Related Terms
Scancell Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a EBIT per Share of $-0.01 as of Oct. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #801 out of 1180 companies in the Biotechnology industry, placing it in the top 67.9%.
Is Scancell Holdings' EBIT per Share too high?
Scancell Holdings' current EBIT per Share is $-0.01. Based on the distribution chart, Scancell Holdings ranks #801 out of 1180 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #801 out of 1180 companies for EBIT per Share. This places Scancell Holdings in the lower half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,180 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current EBIT per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current EBIT per Share of $-0.01. The current EBIT per Share is $-0.01. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current EBIT per Share is $-0.01 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score
Get the complete analysis for SCNLF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
